Amyn Alidina, MD
Medical Oncology · Albuquerque, NMNPI 1821088063
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,299 of the $1,674 with a category attached, or 77.6%. It is spread thinly across 31 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $657 and has fallen 81.0% since, to $125 in 2025.
Across 60 payments — averaging $27.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$257
- E.r. Squibb & Sons, L.L.C.$185
- Merck$156
- Boston Scientific$129
- Blue Earth Diagnostics$123
- Progenics Pharmaceuticals, Inc.$104
- plus $721 from 25 others
Across 15 payments — averaging $273.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$4K
What the payments were for
- Food & beverage$1,29978%
- Education$37522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $257 |
| E.r. Squibb & Sons, L.L.C. | 5 | $185 |
| Merck | 12 | $156 |
| Boston Scientific | 1 | $129 |
| Blue Earth Diagnostics | 1 | $123 |
| Progenics Pharmaceuticals, Inc. | 1 | $104 |
| Gilead(2 entities) | 4 | $84 |
| Regeneron Healthcare Solutions, Inc. | 2 | $73 |
| Karyopharm Therapeutics Inc. | 4 | $50 |
| Seagen Inc. | 2 | $50 |
| Bristol Myers Squibb | 2 | $43 |
| AstraZeneca | 2 | $42 |
| Pfizer | 2 | $35 |
| Sanofi | 1 | $31 |
| Genmab U.S., Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $26 |
| Eisai Inc. | 1 | $25 |
| Legend Biotech USA Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Adaptive Biotechnologies Corporation | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| AbbVie | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Incyte Corporation | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Beigene USA, Inc. | 1 | $15 |
| Axonics, Inc. | 1 | $14 |
| EMD Serono, Inc. | 1 | $13 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TheraSphere Y90 Glass Microspheres 10 GBq$129
- POSLUMA$123
- DARZALEX$121
- TECVAYLI$121
- PYLARIFY$104
How this compares
Too few medical oncology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 27 | $372,331 |
| CabometyxCabozantinib S-Malate | 13 | $328,246 |
| JakafiRuxolitinib Phosphate | 12 | $250,690 |
| KisqaliRibociclib Succinate | 11 | $175,974 |
| GleevecImatinib Mesylate | 11 | $112,015 |
| BrukinsaZanubrutinib | 12 | $84,792 |
| XareltoRivaroxaban | 105 | $83,575 |
| Abiraterone Acetate | 34 | $59,835 |
| ForteoTeriparatide | 11 | $54,928 |
| EliquisApixaban | 49 | $39,361 |
| Exemestane | 15 | $2,801 |
| Hydroxyurea | 90 | $2,771 |
| Tamoxifen Citrate | 45 | $1,364 |
| Ondansetron OdtOndansetron | 73 | $999 |
| Dexamethasone | 49 | $989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $16 | $250,69012 claims |
| Beigene USA, Inc.Brukinsa | $15 | $84,79212 claims |
| Johnson & JohnsonXarelto | $257 | $83,575105 claims |
| PfizerEliquis | $35 | $39,36149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Albuquerque
- Annette FontaineAlbuquerque$208K
- Katherine SanchezAlbuquerque$26K
- Atul KumarAlbuquerque$9K
- Sofia Palacio CardenasAlbuquerque$5K
- Malcolm PurdyAlbuquerque$3K
- Ronald KubicaAlbuquerque$1K
- Joseph EkofoAlbuquerque$195
- Colbert ParkerAlbuquerque$103
- Richard GiudiceAlbuquerque$0
- Wadih ArapAlbuquerque$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.